Bionano Genomics, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
~$3.6
Price-to-sales vs peers
Base case. Range ~$3.6–$17. Sales per share times peers' typical price-to-sales; used only when earnings are negative.
No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.
Bionano Genomics, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Revenue for the twelve months to June 2026 was $30m, up 10.0% on a year earlier, faster than the 1.0% growth a quarter earlier. Free-cash-flow margin rose to -67.9% from -95.0% a year earlier. Operating margin widened to -106.7% from -262.9%. It passes 2 of our 2 financial-health checks.
Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Bionano Genomics, Inc.'s trailing-twelve-month revenue grew 10.0% year on year, with a free-cash-flow margin of -67.9%. Where it stands out: change in growth rate of +9.1pp ranks 7 of 54 life sciences tools & services companies we cover. Where it lags: net margin of -106.6% ranks 44 of 54 life sciences tools & services companies we cover.
Current signal Gross margin expanding: TTM gross margin reached 47.5%, up 42.5pp year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
The company also guided to revenue guidance of $31.00m to $33.00m for the full year 2026.
We value Bionano Genomics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.32 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$3.6 ~$4.7–$17 | Included, half weight |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$3.6 ~$3.6–$17 | 1 model |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Bionano Genomics, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Share price | $3144.00 | $744.00 | $1848.00 | $1794.00 | $876.00 | $113.40 | $17.40 | $1.53 |
| Market value | $74.2bn | $18.6bn | $321.1bn | $827.6bn | $422.2bn | $65m | $22m | $8m |
| + Net debt (− = net cash) | −$7m | $5m | −$21m | −$25m | −$5m | −$18m | −$9m | −$3m |
| Enterprise value | $74.2bn | $18.6bn | $321.1bn | $827.6bn | $422.2bn | $47m | $13m | $5m |
| Multiples | ||||||||
| Price / sales | n/m | n/m | n/m | n/m | n/m | 1.8x | 0.7x | 0.3x |
| Price / earnings | — | — | — | — | — | — | — | — |
| Price / free cash flow | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
Weak moat
How hard Bionano Genomics's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
Cash operating profit has been a median -40.1% of total assets over 8 years.
Gross margin has been a median 29.0%, moving by 13.0 percentage points (standard deviation) across 9 years.
Operating margin has been a median -356.8%; its worst year was -509.3%.
Free cash flow was positive in 0 of 8 years, at a median -331.0% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (16 before it).
Next results: November 10, 2026, after the close. Analysts expect revenue of $8m and EPS of −$0.45 (range −$0.45 to −$0.45) for the quarter.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$2.14 | +56% | $32m | +14% |
| Next | −$0.97 | +55% | $43m | +33% |
The consensus EPS forecast for the current fiscal year is −21.0% on 90 days ago. In the last 30 days, 1 analyst raised Bionano Genomics, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$2.71 | −$1.11 |
| 60 days ago | −$2.13 | −$0.97 |
| 30 days ago | −$2.13 | −$0.97 |
| 7 days ago | −$2.13 | −$0.97 |
| Now | −$2.14 | −$0.97 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.67 | −$0.60 | +11.1% |
| Mar 2026 | −$0.95 | −$0.75 | +21.4% |
| Dec 2025 | −$4.14 | −$0.03 | +99.3% |
| Sept 2025 | −$2.34 | −$1.59 | +32.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| BNGO | −3% | −51% | −87% | −85% | −91% | −24% |
| Industry peers (median) | +5% | −53% | −3% | −13% | −2% | +16% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| BNGO | 17% | 42% | 25% | 25% | 33% | 46% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| BNGO | −81% | −62% | −94% | −90% | −92% | −38% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since August 21, 2018: 100% from February 16, 2021 to July 30, 2026. Getting back needed a 881221% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 10, 2026 | +2.6% | −0.3% | +2.6% | +1.7% |
| May 13, 2026 | −5.6% | +1.4% | −1.6% | −7.9% |
| March 23, 2026 | +2.6% | +0.7% | −1.7% | +8.7% |
| January 12, 2026 | 0.0% | 0.0% | −8.9% | −27.8% |
| November 13, 2025 | −5.0% | −1.7% | −6.9% | −3.7% |
| August 14, 2025 | −6.2% | −0.2% | +27.5% | −14.5% |
| May 14, 2025 | −0.5% | +0.6% | −8.4% | −7.6% |
| March 31, 2025 | +6.9% | +1.0% | +1.7% | +37.6% |
| January 13, 2025 | −8.7% | +0.3% | −21.7% | −61.1% |
| November 13, 2024 | 0.0% | −0.6% | −19.2% | −7.7% |
| October 10, 2024 | −11.9% | +0.4% | −21.4% | −33.3% |
| August 7, 2024 | −21.6% | +1.6% | −17.6% | −13.7% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q3 | $33.6M |
| FY23 Q4 | $36.1M |
| FY24 Q1 | $37.5M |
| FY24 Q2 | $36.6M |
| FY24 Q3 | $33.3M |
| FY24 Q4 | $30.8M |
| FY25 Q1 | $28.5M |
| FY25 Q2 | $27.4M |
| FY25 Q3 | $28.7M |
| FY25 Q4 | $28.5M |
| FY26 Q1 | $28.7M |
| FY26 Q2 | $30.2M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY23 Q3 | 29.8% |
| FY23 Q4 | 29.9% |
| FY24 Q1 | 26.9% |
| FY24 Q2 | 16.1% |
| FY24 Q3 | -0.8% |
| FY24 Q4 | -14.8% |
| FY25 Q1 | -24.0% |
| FY25 Q2 | -25.0% |
| FY25 Q3 | -13.8% |
| FY25 Q4 | -7.4% |
| FY26 Q1 | 1.0% |
| FY26 Q2 | 10.0% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY23 Q3 | -677.8% |
| FY23 Q4 | -596.0% |
| FY24 Q1 | -556.5% |
| FY24 Q2 | -509.3% |
| FY24 Q3 | -351.0% |
| FY24 Q4 | -337.9% |
| FY25 Q1 | -285.7% |
| FY25 Q2 | -262.9% |
| FY25 Q3 | -127.9% |
| FY25 Q4 | -116.9% |
| FY26 Q1 | -114.0% |
| FY26 Q2 | -106.7% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY23 Q3 | -386.5% |
| FY23 Q4 | -346.6% |
| FY24 Q1 | -322.7% |
| FY24 Q2 | -287.5% |
| FY24 Q3 | -276.6% |
| FY24 Q4 | -223.9% |
| FY25 Q1 | -153.0% |
| FY25 Q2 | -95.0% |
| FY25 Q3 | -65.0% |
| FY25 Q4 | -57.3% |
| FY26 Q1 | -67.1% |
| FY26 Q2 | -67.9% |
| Fiscal year | 2017 Dec 2017 | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income | ||||||||||
| Revenue | 10 | 12 | 10 | 9 | 18 | 28 | 36 | 31 | 29 | 30 |
| Gross profit | 3 | 3 | 3 | 3 | 4 | 6 | 10 | 0 | 13 | 14 |
| EBITDA | −22 | −19 | −25 | −37 | −74 | −122 | −202 | −90 | −24 | −24 |
| Operating income | −23 | −20 | −26 | −39 | −77 | −132 | −215 | −104 | −33 | −32 |
| Net income | −23 | −18 | −30 | −41 | −72 | −133 | −232 | −112 | −26 | −32 |
| Diluted EPS | −$2595.00 | −$783.00 | −$1194.00 | −$234.00 | −$15.60 | −$274.80 | −$408.60 | −$88.13 | −$4.85 | — |
| Growth (year on year) | ||||||||||
| Revenue | — | +26.3% | −15.6% | −16.1% | +111.5% | +54.6% | +29.9% | −14.8% | −7.4% | +10.0% |
| Margins | ||||||||||
| Gross margin | 36.6% | 27.4% | 33.2% | 32.6% | 21.5% | 21.4% | 26.5% | 1.2% | 46.3% | 47.5% |
| EBITDA margin | −228.5% | −159.1% | −244.3% | −436.0% | −410.2% | −439.1% | −558.0% | −292.3% | −83.5% | −80.1% |
| Operating margin | −244.3% | −170.1% | −255.4% | −453.4% | −428.8% | −473.7% | −596.0% | −337.9% | −116.9% | −106.7% |
| Net margin | −245.8% | −154.1% | −294.3% | −483.4% | −402.8% | −476.9% | −643.7% | −364.0% | −92.6% | −106.6% |
| Free-cash-flow margin | −229.7% | −169.0% | −292.1% | −450.6% | −400.0% | −448.9% | −346.6% | −223.9% | −57.3% | −67.9% |
| Cash flow | ||||||||||
| Cash from operations | −21 | −20 | −30 | −38 | −72 | −125 | −125 | −69 | −16 | −20 |
| Capital spending | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −22 | −20 | −30 | −38 | −72 | −125 | −125 | −69 | −16 | −20 |
| Stock-based pay | 0 | 1 | 1 | 2 | 10 | 22 | 15 | 10 | 5 | 4 |
| Free cash flow after stock pay | −22 | −21 | −31 | −40 | −82 | −147 | −140 | −79 | −21 | −24 |
| Balance sheet | ||||||||||
| Cash | 1 | 17 | 17 | 38 | 25 | 5 | 18 | 9 | 3 | 4 |
| Total debt | 7 | 10 | 22 | 18 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative = net cash) | 6 | −7 | 5 | −21 | −25 | −5 | −18 | −9 | −3 | −4 |
| Diluted shares | — | 24m | 25m | 174m | 461m | 482m | — | 1m | 5m | — |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 6 | 8 | 6 | 7 | 7 | 8 | 7 | 8 |
| Gross profit | −8 | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| EBITDA | −38 | −10 | −6 | −7 | −6 | −6 | −6 | −6 |
| Operating income | −44 | −12 | −8 | −8 | −9 | −9 | −8 | −7 |
| Net income | −44 | −20 | −3 | −7 | −9 | −8 | −8 | −7 |
| Diluted EPS | −$30.92 | −$7.95 | −$1.15 | −$1.99 | −$1.59 | −$0.03 | −$0.76 | −$0.64 |
| Growth (year on year) | ||||||||
| Revenue | −34.8% | −23.9% | −26.4% | −13.4% | +21.3% | −2.6% | +3.6% | +21.4% |
| Margins | ||||||||
| Gross margin | −139.1% | 41.9% | 45.5% | 51.6% | 45.7% | 42.7% | 48.6% | 52.8% |
| EBITDA margin | −630.2% | −116.9% | −93.4% | −101.0% | −83.6% | −78.0% | −83.6% | −76.1% |
| Operating margin | −722.9% | −146.3% | −131.1% | −115.8% | −115.9% | −107.4% | −118.1% | −88.3% |
| Net margin | −728.6% | −246.5% | −48.0% | −101.8% | −115.4% | −99.8% | −124.2% | −90.8% |
| Free-cash-flow margin | −219.2% | −79.7% | −42.8% | −51.8% | −80.3% | −52.5% | −85.5% | −57.2% |
| Cash flow | ||||||||
| Cash from operations | −13 | −7 | −3 | −3 | −6 | −4 | −6 | −5 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −13 | −7 | −3 | −3 | −6 | −4 | −6 | −5 |
| Stock-based pay | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| Free cash flow after stock pay | −16 | −8 | −4 | −5 | −7 | −5 | −6 | −6 |
| Last 12 months unless stated | BNGO | MXCT | RPID | OABI | TKNO | CSBR | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $30m | $31m | $35m | $40m | $44m | $61m | $229m |
| Revenue growth, last 12 months | 10.0% | −13.2% | 16.1% | 90.6% | 12.3% | 6.7% | 6.9% |
| Revenue growth, 3-year average | −1.4% | −8.6% | 22.5% | −14.7% | 3.7% | 4.8% | 2.9% |
| Revenue growth, latest quarter | 21.4% | −14.5% | 10.9% | 78.3% | 18.5% | 8.8% | 8.5% |
| Gross margin | 47.5% | 79.2% | — | — | 34.6% | 49.8% | 51.9% |
| Operating margin | −106.7% | −134.6% | −141.5% | −115.9% | −36.2% | −1.7% | −14.3% |
| Operating margin, 3-year average | −293.0% | −128.7% | −171.1% | −278.2% | −61.6% | −1.2% | −22.4% |
| Net margin | −106.6% | −114.8% | −145.6% | −108.1% | −38.4% | −1.8% | −16.1% |
| Cash from operations / revenue | −67.9% | −74.0% | −113.9% | 6.6% | −14.4% | −9.2% | 1.3% |
| Free-cash-flow margin | −67.9% | −76.1% | −114.8% | 5.9% | −16.8% | −10.1% | −2.2% |
| Free-cash-flow margin, 3-year average | −150.1% | −79.7% | −143.5% | −130.3% | −32.0% | −0.4% | 0.6% |
| Stock pay / revenue | 11.6% | 16.0% | 12.3% | 32.7% | 6.7% | 3.0% | 4.4% |
| Change in share count | — | 1.0% | 4.4% | 19.2% | 1.0% | −2.4% | 1.0% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 10.0% | 6.9% | 21 of 54 |
| Change in growth rate Growth | +9.1pp | +0.4pp | 7 of 54 |
| Gross margin Profitability | 47.5% | 52.0% | 27 of 45 |
| Operating margin Profitability | -106.7% | -14.3% | 42 of 52 |
| Net margin Profitability | -106.6% | -12.2% | 44 of 54 |
| Free-cash-flow margin Cash generation | -67.9% | -1.3% | 44 of 54 |
| Stock pay as % of revenue Cash generation | 11.6% | 4.4% | 36 of 53 |
| Days sales outstanding Balance sheet | 53 days | 62 days | 16 of 48 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $26.7M | 93.8% | ▼ 1.0% |
| Consumable Revenue (part of Products) | $14M | 52.2% | ▲ 9.4% |
| Software Revenue (part of Products) | $6.4M | 24.0% | ▲ 3.5% |
| Instrument Revenue (part of Products) | $6.4M | 23.8% | ▼ 20.9% |
| Other | $1.8M | 6.2% | ▼ 53.2% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| EMEA | $14.1M | 49.5% | ▼ 0.9% |
| Americas | $12.2M | 42.7% | ▼ 10.8% |
| Asia Pacific | $2.2M | 7.8% | ▼ 23.3% |
From Bionano Genomics, Inc.'s 10-K filed March 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Gsa Capital Partners LLP | $170,000 | 150K | 21.2% | ▼ 57.5% |
| Carret Asset Management, LLC | $141,250 | 125K | 17.6% | ▲ 78.6% |
| Geode Capital Management, LLC | $101,693 | 90K | 12.7% | ▼ 46.3% |
| Vanguard Capital Management LLC | $93,098 | 82K | 11.6% | ▲ 21.0% |
| Vanguard Fiduciary Trust Co | $58,283 | 52K | 7.3% | 0.0% |
| Renaissance Technologies LLC | $57,743 | 51K | 7.2% | ▲ 4.9% |
| Jane Street Group, LLC | $40,373 | 36K | 5.0% | New |
| Prudential Financial Inc | $35,708 | 32K | 4.5% | ▲ 12.9% |
| Northern Trust Corp | $27,754 | 25K | 3.5% | ▲ 19.7% |
| Xtx Topco Ltd | $18,413 | 16K | 2.3% | New |
| Engineers Gate Manager LP | $13,546 | 12K | 1.7% | ▲ 1.1% |
| HRT Financial LP | $13,000 | 12K | 1.6% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Bionano Genomics, Inc.'s complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Luderer Albert Interim Chief Executive | September 4, 2026 | Buy | 4,000 | $1.21 | $4,840 |
| Luderer Albert Interim Chief Executive | August 21, 2026 | Buy | 4,000 | $1.22 | $4,880 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around October 23, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
